Literature DB >> 15308733

In vivo analysis of the 3' untranslated region of GB virus B after in vitro mutagenesis of an infectious cDNA clone: persistent infection in a transfected tamarin.

Jae-Hwan Nam1, Kristina Faulk, Ronald E Engle, Sugantha Govindarajan, Marisa St Claire, Jens Bukh.   

Abstract

GB virus B (GBV-B), the virus most closely related to hepatitis C virus (HCV), infects tamarins and causes acute hepatitis. The 3' untranslated region (UTR) of an infectious GBV-B clone (pGBB) has a proximal short sequence followed by a poly(U) tract and a 3' terminal sequence. Our investigators previously demonstrated that the 3' terminal sequence was critical for in vivo infectivity. Here, we tested the effect of deleting the short sequence and/or the poly(U) tract from pGBB; infectivity of each mutant was tested by intrahepatic transfection of two tamarins with transcribed RNA. A mutant lacking both regions was not viable. However, mutants lacking either the short sequence or the poly(U) tract were viable. All four tamarins had a wild-type-like acute infection and developed acute hepatitis. Whereas we found that five tamarins transfected with the wild-type clone pGBB had acute resolving infection, one tamarin transfected with the poly(U) deletion mutant became persistently infected. This animal had viremia and hepatitis until its death at week 90. The genomes recovered at weeks 2, 7, 15, 20, 60, and 90 lacked the poly(U) stretch. Eight amino acid changes were identified at week 90. One change, in the putative p7 protein, was dominant at week 15. Thus, persistence of GBV-B, like persistence of HCV, was associated with the emergence of virus variants. Four tamarins inoculated with serum collected at weeks 2 and 90 from the tamarin with persistent infection had an acute resolving infection. Nonetheless, the demonstration that GBV-B can persist in tamarins strengthens its relevance as a surrogate model for the study of HCV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308733      PMCID: PMC506939          DOI: 10.1128/JVI.78.17.9389-9399.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees.

Authors:  J Bukh; C L Apgar; S Govindarajan; R H Purcell
Journal:  J Med Virol       Date:  2001-12       Impact factor: 2.327

2.  Nucleoside triphosphatase and RNA helicase activities associated with GB virus B nonstructural protein 3.

Authors:  W Zhong; P Ingravallo; J Wright-Minogue; A Skelton; A S Uss; R Chase; N Yao; J Y Lau; Z Hong
Journal:  Virology       Date:  1999-09-01       Impact factor: 3.616

3.  Genetic analysis of sequences in the 3' nontranslated region of hepatitis C virus that are important for RNA replication.

Authors:  Peter Friebe; Ralf Bartenschlager
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Generation of infectious and transmissible virions from a GB virus B full-length consensus clone in tamarins.

Authors:  Andrea Sbardellati; Elisa Scarselli; Ernst Verschoor; Amedeo De Tomassi; Domenico Lazzaro; Cinzia Traboni
Journal:  J Gen Virol       Date:  2001-10       Impact factor: 3.891

5.  Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.

Authors:  M E Major; K Mihalik; J Fernandez; J Seidman; D Kleiner; A A Kolykhalov; C M Rice; S M Feinstone
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  3' nontranslated RNA signals required for replication of hepatitis C virus RNA.

Authors:  MinKyung Yi; Stanley M Lemon
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia.

Authors:  Robert E Lanford; Deborah Chavez; Lena Notvall; Kathleen M Brasky
Journal:  Virology       Date:  2003-06-20       Impact factor: 3.616

8.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.

Authors:  Robert Thimme; Jens Bukh; Hans Christian Spangenberg; Stefan Wieland; Janell Pemberton; Carola Steiger; Sugantha Govindarajan; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-19       Impact factor: 11.205

9.  Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA.

Authors:  Annette Martin; Francis Bodola; David V Sangar; Kathryn Goettge; Vsevolod Popov; Rene Rijnbrand; Robert E Lanford; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-07       Impact factor: 11.205

10.  Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees.

Authors:  Jens Bukh; Thomas Pietschmann; Volker Lohmann; Nicole Krieger; Kristina Faulk; Ronald E Engle; Sugantha Govindarajan; Max Shapiro; Marisa St Claire; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

View more
  21 in total

1.  Characterization of a canine homolog of hepatitis C virus.

Authors:  Amit Kapoor; Peter Simmonds; Gisa Gerold; Natasha Qaisar; Komal Jain; Jose A Henriquez; Cadhla Firth; David L Hirschberg; Charles M Rice; Shelly Shields; W Ian Lipkin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-24       Impact factor: 11.205

2.  Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins.

Authors:  Shingo Takikawa; Ronald E Engle; Kristina N Faulk; Suzanne U Emerson; Robert H Purcell; Jens Bukh
Journal:  J Gen Virol       Date:  2009-11-11       Impact factor: 3.891

3.  Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model.

Authors:  Sheetal Trivedi; Satyapramod Murthy; Himanshu Sharma; Alex S Hartlage; Arvind Kumar; Sashi V Gadi; Peter Simmonds; Lokendra V Chauhan; Troels K H Scheel; Eva Billerbeck; Peter D Burbelo; Charles M Rice; W Ian Lipkin; Kurt Vandegrift; John M Cullen; Amit Kapoor
Journal:  Hepatology       Date:  2018-05-21       Impact factor: 17.425

4.  Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogens.

Authors:  Nicolas Brezillon; Dina Kremsdorf; Mary C Weiss
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

5.  The marmoset model of GB virus B infections: adaptation to host phenotypic variation.

Authors:  Trudie Weatherford; Deborah Chavez; Kathleen M Brasky; Robert E Lanford
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  Functional analyses of GB virus B p13 protein: development of a recombinant GB virus B hepatitis virus with a p7 protein.

Authors:  Shingo Takikawa; Ronald E Engle; Suzanne U Emerson; Robert H Purcell; Marisa St Claire; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

7.  Lack of adaptation of chimeric GB virus B/hepatitis C virus in the marmoset model: possible effects of bottleneck.

Authors:  Trudie Weatherford; Deborah Chavez; Kathleen M Brasky; Stanley M Lemon; Annette Martin; Robert E Lanford
Journal:  J Virol       Date:  2009-05-27       Impact factor: 5.103

Review 8.  New animal models for hepatitis C viral infection and pathogenesis studies.

Authors:  Dina Kremsdorf; Nicolas Brezillon
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

9.  Antiviral activity and host gene induction by tamarin and marmoset interferon-alpha and interferon-gamma in the GBV-B primary hepatocyte culture model.

Authors:  Deborah Chavez; Bernadette Guerra; Robert E Lanford
Journal:  Virology       Date:  2009-06-07       Impact factor: 3.616

10.  A cooperative interaction between nontranslated RNA sequences and NS5A protein promotes in vivo fitness of a chimeric hepatitis C/GB virus B.

Authors:  Lucile Warter; Lisette Cohen; Yann Benureau; Deborah Chavez; Yan Yang; Francis Bodola; Stanley M Lemon; Cinzia Traboni; Robert E Lanford; Annette Martin
Journal:  PLoS One       Date:  2009-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.